Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ASGR1 | P07306 | 1/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.33 |
| ▸ | CTSD | P07339 | 1/20 | 0.31 |
| ▸ | CTSL | P07711 | 1/20 | 0.31 |
| ▸ | CTSB | P07858 | 1/20 | 0.31 |
| ▸ | CTSS | P25774 | 1/20 | 0.31 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.30 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.30 |
| ▸ | RELA | Q04206 | 1/20 | 0.30 |
| ▸ | BRD4 | O60885 | 1/20 | 0.30 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30885813 | 0.84 | ASGR1 (0.32) | ASGR1HDAC6HDAC1HDAC2CTSD | |
| SCHEMBL23539397 | 0.83 | GRM1 (0.34) | ASGR1HDAC6HDAC1HDAC2 | |
| SCHEMBL23225475 | 0.83 | ASGR1 (0.32) | ASGR1HDAC6HDAC1HDAC2 | |
| SCHEMBL23539122 | 0.80 | FOLH1 (0.33) | ASGR1HDAC6HDAC1HDAC2 | |
| SCHEMBL30059357 | 0.80 | CTSS (0.36) | ASGR1CTSDCTSLCTSBCTSS | |
| SCHEMBL17586292 | 0.79 | ASGR1 (0.32) | ASGR1HDAC6HDAC1HDAC2CTSD | |
| SCHEMBL17582445 | 0.79 | ASGR1 (0.33) | ASGR1 | |
| SCHEMBL23284466 | 0.78 | ASGR1 (0.31) | ASGR1HDAC6HDAC1HDAC2 | |
| SCHEMBL17586283 | 0.78 | ASGR1 (0.31) | ASGR1HDAC6HDAC1HDAC2 | |
| SCHEMBL19373428 | 0.78 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230026872-A1 | METHODS FOR TREATING HEMATOLOGICAL MALIGNANCIES AND EWING'S SARCOMA | KURA ONCOLOGY, INC. | 2023-01-26 | — | — | US | disclosed |
| US-10752639-B2 | Bridged bicyclic inhibitors of menin-MLL and methods of use | KURA ONCOLOGY, INC. (US) | 2020-08-25 | — | — | US | disclosed |
| US-20190092783-A1 | BRIDGED BICYCLIC INHIBITORS OF MENIN-MLL AND METHODS OF USE | KURA ONCOLOGY, INC. (US) | 2019-03-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230026872-A1 | METHODS FOR TREATING HEMATOLOGICAL MALIGNANCIES AND EWING'S SARCOMA | MEN1, DIAPH1, EWSR1 | ASGR1 2966/4885HDAC6 572/4885HDAC1 1092/4885 |
| US-10752639-B2 | Bridged bicyclic inhibitors of menin-MLL and methods of use | MLLT1, MEN1, MLLT3 | ASGR1 4287/4885HDAC6 1568/4885HDAC1 89/4885 |
| US-20190092783-A1 | BRIDGED BICYCLIC INHIBITORS OF MENIN-MLL AND METHODS OF USE | MLLT1, MEN1, BMI1 | ASGR1 4307/4885HDAC6 1663/4885HDAC1 204/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.